- Home
- RPRX vs CYBR Comparison
RPRX vs CYBR Comparison
Compare RPRX & CYBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- CYBR
- Stock Information
- Founded
- RPRX 1996
- CYBR 1999
- Country
- RPRX United States
- CYBR Israel
- Employees
- RPRX N/A
- CYBR N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- CYBR Computer Software: Prepackaged Software
- Sector
- RPRX Health Care
- CYBR Technology
- Exchange
- RPRX Nasdaq
- CYBR Nasdaq
- Market Cap
- RPRX 11.8B
- CYBR 12.4B
- IPO Year
- RPRX 2020
- CYBR 2014
- Fundamental
- Price
- RPRX $26.43
- CYBR $319.73
- Analyst Decision
- RPRX Strong Buy
- CYBR Strong Buy
- Analyst Count
- RPRX 6
- CYBR 29
- Target Price
- RPRX $41.67
- CYBR $327.10
- AVG Volume (30 Days)
- RPRX 3.1M
- CYBR 565.8K
- Earning Date
- RPRX 11-06-2024
- CYBR 11-13-2024
- Dividend Yield
- RPRX 3.18%
- CYBR N/A
- EPS Growth
- RPRX 518.56
- CYBR N/A
- EPS
- RPRX 2.55
- CYBR 0.27
- Revenue
- RPRX $2,266,003,000.00
- CYBR $909,462,000.00
- Revenue This Year
- RPRX $12.38
- CYBR $27.72
- Revenue Next Year
- RPRX $11.26
- CYBR $23.19
- P/E Ratio
- RPRX $10.35
- CYBR $1,117.67
- Revenue Growth
- RPRX N/A
- CYBR 30.31
- 52 Week Low
- RPRX $25.10
- CYBR $191.25
- 52 Week High
- RPRX $31.66
- CYBR $332.05
- Technical
- Relative Strength Index (RSI)
- RPRX 45.67
- CYBR 65.00
- Support Level
- RPRX $25.47
- CYBR $291.52
- Resistance Level
- RPRX $26.67
- CYBR $332.05
- Average True Range (ATR)
- RPRX 0.64
- CYBR 12.02
- MACD
- RPRX 0.05
- CYBR 3.18
- Stochastic Oscillator
- RPRX 40.80
- CYBR 79.01
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About CYBR CyberArk Software Ltd.
CyberArk is a cybersecurity vendor focused on the identity market. The company's core privileged access management offering is a market leader within that subsegment, with more than half of the Fortune 500 CyberArk customers. The identity security vendor was founded in 1999 and has around 9,000 customers across various industries. While historically, CyberArk has sold its security solutions primarily via on-premises licenses, over the past few years, it has transitioned to a subscription, recurring revenue model.